Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
The purpose of this clinical trial was to evaluate the efficacy and tolerability of the sequential therapy of VCD/IE in the patients with ESFT.
Ewing's Sarcoma
DRUG: VCR, CTX, ADM; IFO, VP-16
Response Rate, every two cycles
Toxicity, every cycle
80-90% patients of ESFT will develope disease progression during the period of local treatment (surgery or radiation). The survival has been improved in these 30 years due to chemotherapy. VCD/IE is widely used in the world for the patients with ESFT, but it is rarely used in China due to its high dosage.